Sign in
CompletedNo phase

NDS and NSS for Screening Diabetic Neuropathy

Key facts

Who runs it
Chulalongkorn University
Where
Thailand1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
228 people enrolled
Started
14 Mar 2024
Ended
13 Mar 2026
Type of study
Observational
Record updated
29 April 2026

Who can take part

Age
30 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Adults aged 30 to 65 years
  • Diagnosed with diabetes mellitus (type 1 or type 2) by a physician
  • Able and willing to provide informed consent
  • Willing to undergo clinical evaluation and neurophysiological testing, including nerve conduction studies

Who cannot take part

  • Exposure to neurotoxic agents (e.g., drugs, heavy metals)
  • History of other causes of peripheral neuropathy (e.g., nutritional deficiency, alcohol-related neuropathy, chronic kidney disease)
  • Known neuromuscular or neurological disorders (e.g., myopathy, hereditary neuropathy, Guillain-Barré syndrome, chronic inflammatory neuropathy)
  • Presence of lower limb conditions interfering with assessment (e.g., amputation, chronic wounds, significant edema)
  • Inability to communicate or complete study procedures

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Diabetic sensorimotor polyneuropathy is a common complication of diabetes mellitus that can lead to pain, sensory loss, foot ulcers, and disability. Early detection is important, but standard diagnostic tests such as nerve conduction studies are not always easily accessible in routine clinical practice.

Read full original descriptionShow less

This study aims to evaluate the accuracy and reliability of two simple clinical tools, the Neuropathy Disability Score (NDS) and the Neuropathy Symptom Score (NSS), for screening diabetic peripheral neuropathy. These tools are based on patient-reported symptoms and bedside neurological examination and may provide a practical alternative for early detection.

In this cross-sectional diagnostic accuracy study, adult patients with diabetes will be recruited from King Chulalongkorn Memorial Hospital. Participants will undergo clinical assessments, questionnaires, laboratory investigations, and neurophysiological testing, including nerve conduction studies, which will serve as the reference standard. The performance of NDS and NSS will be analyzed to determine their sensitivity, specificity, and overall diagnostic value.

The results of this study may support the use of simple, accessible screening tools for early identification of diabetic neuropathy, potentially improving patient care and reducing complications.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Utilizing the Neuropathy Disability Score and Neuropathy Symptom Score for Screening Diabetic Sensorimotor Polyneuropathy
Record updated
29 April 2026